• Perry J, Zuraw L, Neuro-Oncology Disease Site Group. Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 May 8. 23 p. (Evidence-based series; no. 9-2). [38 references]

• The use of concurrent temozolomide during radiation therapy and post-radiation adjuvant temozolomide is recommended for all patients with newly diagnosed glioblastoma multiforme who are fit for radical therapy. Temozolomide should be considered in patients with malignant gliomas.
• Younger patients, patients with anaplastic (grade 3) astrocytoma, and patients with pure or mixed oligodendroglioma, are more likely to harbour chemosensitive tumours, and adjuvant chemotherapy may be an option in these cases. However, there is no evidence of a survival advantage from adjuvant chemotherapy in these patients, and treatment-related adverse effects and their impact upon quality of life are poorly studied.
• Patients should be provided with information about the controversies surrounding the benefit and optimal timing of such treatment.

None provided

The recommendations are supported by meta-analyses and randomized controlled trials (RCTs).

• Perry J, Zuraw L, Neuro-Oncology Disease Site Group. Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 May 8. 23 p. (Evidence-based series; no. 9-2). [38 references]

Not applicable: The guideline was not adapted from another source.

2004 Mar 10 (revised 2006 May 8)

Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]

The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

Cancer Care Ontario
Ontario Ministry of Health and Long-Term Care

Provincial Neuro-oncology Cancer Disease Site Group

Members of the Neuro-oncology Cancer Disease Site Group (DSG) involved in the development of this systematic review were polled for potential conflicts of interest.

None available

This NGC summary was completed by ECRI on June 30, 2004. The information was verified by the guideline developer on July 19, 2004. This NGC summary was updated by ECRI on August 16, 2006. The updated information was verified by the guideline developer on August 23, 2006.